​

Prelude Therapeutics (PRLD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PRLD Stock Forecast

Prelude Therapeutics (PRLD) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $6.25, with a high of $10.00 and a low of $3.00. This represents a 80.64% increase from the last price of $3.46.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $6.25 Low: $3 Last Closed Price: $3.46

PRLD Stock Rating

Prelude Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 1 Hold (12.50%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 1 5 Strong Sell Sell Hold Buy Strong Buy

PRLD Price Target Upside V Benchmarks

TypeNameUpside
StockPrelude Therapeutics80.64%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.46$3.46$3.46
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2612---3
Mar, 2612---3
Feb, 2612---3
Jan, 2612---3
Dec, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Robert BurnsH.C. Wainwright$5.00$5.17-3.29%44.51%
Jun 20, 2024Peter LawsonBarclays$3.00$3.87-22.48%-13.29%
Mar 13, 2024Reni BenjaminJMP Securities$7.00$4.6251.52%102.31%
Nov 17, 2022H.C. Wainwright$15.00$7.7094.81%333.53%
Nov 15, 2022Morgan Stanley$10.00$8.1023.46%189.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 19, 2024H.C. WainwrightNeutralBuyupgrade
Sep 10, 2024H.C. WainwrightNeutralNeutralhold
Jun 20, 2024BarclaysEqual-WeightUnderweightdowngrade
Dec 19, 2023Morgan StanleyEqual-WeightUnderweightdowngrade
Nov 15, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Feb 28, 2022BarclaysEqual-Weightdowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.02$-1.68$-1.29---
Avg Forecast$-2.04$-1.78$-1.50$-1.26$-1.37$-1.26
High Forecast$-2.01$-1.74$-1.30$-1.18$-1.28$-1.26
Low Forecast$-2.06$-1.83$-1.68$-1.33$-1.46$-1.26
Surprise %-0.98%-5.62%-14.00%---

Revenue Forecast

$5M $12M $19M $26M $33M $40M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$7.00M$12.14M---
Avg Forecast-$2.00M-$8.30M$21.70M$37.88M
High Forecast-$2.00M-$8.30M$21.70M$37.88M
Low Forecast-$2.00M-$8.30M$21.70M$37.88M
Surprise %-250.00%----

Net Income Forecast

$-130M $-118M $-106M $-94M $-82M $-70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.83M$-127.17M$-99.50M---
Avg Forecast$-121.83M$-107.73M$-89.89M$-75.85M$-82.69M$-76.05M
High Forecast$-121.33M$-104.77M$-78.40M$-71.39M$-77.22M$-76.05M
Low Forecast$-124.33M$-110.69M$-101.37M$-80.31M$-88.16M$-76.05M
Surprise %-18.05%10.69%---

PRLD Forecast FAQ

Is Prelude Therapeutics stock a buy?

Prelude Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Prelude Therapeutics is a favorable investment for most analysts.

What is Prelude Therapeutics's price target?

Prelude Therapeutics's price target, set by 8 Wall Street analysts, averages $6.25 over the next 12 months. The price target range spans from $3 at the low end to $10 at the high end, suggesting a potential 80.64% change from the previous closing price of $3.46.

How does Prelude Therapeutics stock forecast compare to its benchmarks?

Prelude Therapeutics's stock forecast shows a 80.64% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Prelude Therapeutics over the past three months?

  • April 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Prelude Therapeutics’s EPS forecast?

Prelude Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.26, marking a -2.33% decrease from the reported $-1.29 in 2025. Estimates for the following years are $-1.37 in 2027, and $-1.26 in 2028.

What is Prelude Therapeutics’s revenue forecast?

Prelude Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $8.3M, reflecting a -31.63% decrease from the reported $12.14M in 2025. The forecast for 2027 is $21.7M, and $37.88M for 2028.

What is Prelude Therapeutics’s net income forecast?

Prelude Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-75.849M, representing a -23.77% decrease from the reported $-99.498M in 2025. Projections indicate $-82.689M in 2027, and $-76.05M in 2028.